Peer reviewed
Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity (STEP 1)
Phase 3 trial showing semaglutide 2.4 mg weekly achieved mean weight loss of 14.9% at 68 weeks.
New England Journal of MedicinePublished Feb 10, 2021Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-semaglutide-step1-2021
Source usage
Linked from 6 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.